The BAX Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the BAX gene in the human HT29 colorectal adenocarcinoma cell line. This polyclonal pool comprises a heterogeneous mix of cells carrying diverse gene-editing events, generated without single-cell cloning. This format provides a genetically diverse model for loss-of-function studies, avoiding potential clonal artifacts while enabling robust bulk functional analyses relevant to colorectal cancer biology.
The HT29 parental line is an epithelial, adherent colorectal adenocarcinoma cell line derived from a 44-year-old female. These cells are well-characterized as a model of the intestinal epithelium and retain the capacity for differentiation, making them suitable for studies of gastrointestinal biology. HT29 cells are widely utilized in colorectal cancer research due to their tumor origin, facilitating investigations of proliferation, metastasis, and therapeutic response. Their ability to form polarized monolayers and express colonocyte markers further enhances their utility as a relevant in vitro system.
BAX encodes a pro-apoptotic Bcl-2 family protein that operates downstream of cellular stress signals. It is activated by p53 and BH3-only proteins like BIM, BID, PUMA, and NOXA, which counteract inhibition by anti-apoptotic BCL-2 and BCL-XL. Activated BAX oligomerizes on the mitochondrial outer membrane, causing permeabilization and cytochrome c release, which triggers apoptosome formation with APAF1 and activation of caspase-9 and caspase-3, executing apoptosis. BAX thus serves as a key conduit linking upstream damage signals to mitochondrial cell death.
In the HT29 setting, BAX knockout impairs the intrinsic apoptotic pathway, conferring resistance to apoptosis induced by DNA damage, serum deprivation, and other stressors. This model allows dissection of BAX’s role in colorectal cancer cell survival and exploration of BAX-independent death mechanisms. As BAX deficiency is common in colorectal cancers, this polyclonal knockout population is valuable for studying tumorigenesis, drug resistance, and synthetic lethal interactions. It provides a physiologically relevant platform to screen for agents that restore apoptosis or bypass BAX deficiency.
Key applications include apoptosis resistance profiling, drug sensitivity screening, tumorigenicity assays, and mechanistic studies of mitochondrial apoptosis. Validation of knockout can be performed by Western blotting and RT-qPCR, while functional assays like Annexin V staining, caspase-3 activity, and cytochrome c release quantify apoptotic competence. Co-immunoprecipitation can map BAX interactions with BCL-2 family proteins, and flow cytometry enables apoptotic marker analysis. This product is ideal for researchers investigating colorectal cancer biology and apoptosis-targeted therapeutics. For further details, please contact Ascent Research.
